MedicalResearch.com Interview Invitation Argonde van Harten From the Alzheimer Center School for Mental Health and Neurosciences, Maastricht University Medical Center, Maastricht, the Netherlands. MedicalResearch.com: What are the main findings of the study? Answer: We found cerebrospinal fluid biomarker evidence of preclinical Alzheimer's disease (AD) predicted cognitive decline in patients with subjective complaints. These patients have cognitive complaints, but are cognitively normal at baseline. Preclinical AD predicted decline in memory performance, executive functions and global cognition over time. Most patients, however, had no evidence of preclinical AD and their cogntive functions generally remained stable over two years. Their memory performance improved. (more…)